To avoid “AI washing,” pharma companies must reinvest in data quality – PharmaLive

To avoid “AI washing,” pharma companies must reinvest in data quality
In contrast to the general public’s lingering unease around generative AI tools such as ChatGPT, the biopharma industry is increasingly looking to AI as its magic cure-all for drug development. The technology’s market capitalization in the space is now forecasted to rise to $11.93 billion by 2033 (compared to just $1.73 billion this year). With 2025 upon us, this investment destines AI for an even greater role in life […]
To avoid “AI washing,” pharma companies must reinvest in data quality – PharmaLive